Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes

被引:7
|
作者
Zipeto, Donato
Matucci, Andrea
Ripamonti, Chiara
Scarlatti, Gabriella
Rossolillo, Paola
Turci, Marco
Sartoris, Silvia
Tridente, Giuseppe
Bertazzoni, Umberto
机构
[1] Univ Verona, Sect Biol & Genet, Dept Moth & Child Biol & Genet, Mol Virol Lab, I-37134 Verona, Italy
[2] CNRS, IPBS, F-31077 Toulouse, France
[3] Policlin GB Rossi, Immunol Sect, Dept Pathol, I-37134 Verona, Italy
[4] Ist Sci San Raffaele, DIBIT, Viral Evolut & Transmiss Unit, I-20132 Milan, Italy
关键词
fusion complex; neutralizing antibodies; membrane fusion;
D O I
10.1016/j.micinf.2006.03.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human immunodeficiency virus-1 (HIV-1) infects cells by membrane fusion that is mediated by the envelope proteins gp120/gp41 and the cellular receptors CD4 and CCR5. During this process, some conserved viral epitopes are temporarily exposed and may induce a neutralizing antibody response when fixed in the fusogenic conformation. These transient structures are conserved and may be effective antigens for use in an anti-HIV-1 vaccine. In this study we tested different conditions of preparation of fusion complexes inducing neutralizing antibodies against both R5 and X4 tropic HIV-1 strains. Cell lines expressing HIV-1 gp120/gp41 and CD4-CCR5 were prepared and conditions for producing fusion complexes were tested. Complexes produced at different temperature and fixative combinations were used to immunize mice. Results indicated that (a) fusion complexes prepared at either 21 degrees C, 30 degrees C or 37 degrees C were immunogenic and induced neutralizing antibodies against both R5 and X4 HIV-1 heterologous isolates; (b) after extensive purification of antibodies there was no cytotoxic effect; (c) complexes prepared at 37 degrees C were more immunogenic and induced higher titers of neutralizing antibodies than complexes prepared at either 21 degrees C or 30 degrees C; (d) the fixative used did not affect the titer of neutralizing antibodies except for glutaraldehyde which was ineffective; (e) the neutralizing activity was retained after CD4-CCR5 antibody removal. The production of higher titers of neutralizing antibody with fusion complexes prepared at 37 degrees C, as compared to lower temperatures, may be related to the induction of antibodies against many different conformation intermediates that subsequently act synergistically at different steps in the fusion process. (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:1424 / 1433
页数:10
相关论文
共 50 条
  • [1] Role of Human Immunodeficiency Virus Type 1 Envelope Structure in the Induction of Broadly Neutralizing Antibodies
    Benjelloun, F.
    Lawrence, P.
    Verrier, B.
    Genin, C.
    Paul, S.
    JOURNAL OF VIROLOGY, 2012, 86 (24) : 13152 - 13163
  • [2] Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate
    Chen, CH
    Jin, L
    Zhu, CB
    Holz-Smith, S
    Matthews, TJ
    JOURNAL OF VIROLOGY, 2001, 75 (14) : 6700 - 6704
  • [3] Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus
    Ahmad, Maham
    Ahmed, Osama M.
    Schnepp, Bruce
    Johnson, Philip R.
    ANNUAL REVIEW OF VIROLOGY, VOL 4, 2017, 4 : 491 - 510
  • [4] Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates
    Golding, H
    Zaitseva, M
    de Rosny, E
    King, LR
    Manischewitz, J
    Sidorov, I
    Gorny, MK
    Zolla-Pazner, S
    Dimitrov, DS
    Weiss, CD
    JOURNAL OF VIROLOGY, 2002, 76 (13) : 6780 - 6790
  • [5] Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus
    Ai Himeno
    Yuki Ishida
    Hiromi Mori
    Kanako Matsuura
    Minako Kikukawa
    Hiromi Sakawaki
    Tomoyuki Miura
    Archives of Virology, 2019, 164 : 1297 - 1308
  • [6] Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus
    Himeno, Ai
    Ishida, Yuki
    Mori, Hiromi
    Matsuura, Kanako
    Kikukawa, Minako
    Sakawaki, Hiromi
    Miura, Tomoyuki
    ARCHIVES OF VIROLOGY, 2019, 164 (05) : 1297 - 1308
  • [7] Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application
    Ding, Chengchao
    Patel, Darshit
    Ma, Yunjing
    Mann, Jamie F. S.
    Wu, Jianjun
    Gao, Yong
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [8] In vivo efficacy of human immunodeficiency virus neutralizing antibodies:: Estimates for protective titers
    Trkola, Alexandra
    Kuster, Herbert
    Rusert, Peter
    von Wyl, Viktor
    Leemann, Christine
    Weber, Rainer
    Stiegler, Gabriela
    Katinger, Hermann
    Joos, Beda
    Guenthard, Huldrych F.
    JOURNAL OF VIROLOGY, 2008, 82 (03) : 1591 - 1599
  • [9] NEUTRALIZING ANTIBODIES IN CATS INFECTED WITH FELINE IMMUNODEFICIENCY VIRUS
    TOZZINI, F
    MATTEUCCI, D
    BANDECCHI, P
    BALDINOTTI, F
    SIEBELINK, K
    OSTERHAUS, A
    BENDINELLI, M
    JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (06) : 1626 - 1629
  • [10] Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization
    Hammonds, J
    Chen, XM
    Fouts, T
    DeVico, A
    Montefiori, D
    Spearman, P
    JOURNAL OF VIROLOGY, 2005, 79 (23) : 14804 - 14814